[go: up one dir, main page]

CY1118664T1 - Απομονωμενο πολυπεπτιδιο των πρωτεϊνων τοξινης α και τοξινης β toy c. difficile και χρησεις αυτου - Google Patents

Απομονωμενο πολυπεπτιδιο των πρωτεϊνων τοξινης α και τοξινης β toy c. difficile και χρησεις αυτου

Info

Publication number
CY1118664T1
CY1118664T1 CY20171100260T CY171100260T CY1118664T1 CY 1118664 T1 CY1118664 T1 CY 1118664T1 CY 20171100260 T CY20171100260 T CY 20171100260T CY 171100260 T CY171100260 T CY 171100260T CY 1118664 T1 CY1118664 T1 CY 1118664T1
Authority
CY
Cyprus
Prior art keywords
toxin
difficile
toy
proteins
tab
Prior art date
Application number
CY20171100260T
Other languages
English (en)
Inventor
Larry Ellingsworth
David Flyer
Jing-Hui Tian
Steven Fuhrmann
Stefanie Kluepfel-Stahl
Gregory Glenn
Kerstin Westritschnig
Original Assignee
Valneva Austria Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44799993&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY1118664(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Valneva Austria Gmbh filed Critical Valneva Austria Gmbh
Publication of CY1118664T1 publication Critical patent/CY1118664T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/08—Clostridium, e.g. Clostridium tetani
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Clostridium (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1267—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria
    • C07K16/1282—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria from Clostridium (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55544—Bacterial toxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/55—Fusion polypeptide containing a fusion with a toxin, e.g. diphteria toxin
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Η παρούσα εφεύρεση παρέχει απομονωμένα πολυπεπτίδια C-TAB.G5 και C-TAB.G5.1 που περιέχουν τις περιοχές δέσμευσης υποδοχέα τοξίνης Α και τοξίνης Β του C. difficile όπως παρατίθενται στις αλληλουχίες αμινοξέων της SEQ ID NO: 2 και SEQ ID NO: 4. Τα απομονωμένα πολυπεπτίδια C-TAB.G5 και C-TAB.G5.1 μπορούν να χρησιμοποιηθούν σε εξουδετέρωση των τοξικών επενεργειών τοξίνης Α και/ή τοξίνης Β του C. difficile.
CY20171100260T 2010-09-03 2017-02-24 Απομονωμενο πολυπεπτιδιο των πρωτεϊνων τοξινης α και τοξινης β toy c. difficile και χρησεις αυτου CY1118664T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US37989210P 2010-09-03 2010-09-03
PCT/EP2011/065304 WO2012028741A1 (en) 2010-09-03 2011-09-05 Isolated polypeptide of the toxin a and toxin b proteins of c. difficile and uses thereof

Publications (1)

Publication Number Publication Date
CY1118664T1 true CY1118664T1 (el) 2017-07-12

Family

ID=44799993

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20171100260T CY1118664T1 (el) 2010-09-03 2017-02-24 Απομονωμενο πολυπεπτιδιο των πρωτεϊνων τοξινης α και τοξινης β toy c. difficile και χρησεις αυτου

Country Status (22)

Country Link
US (7) US9598472B2 (el)
EP (3) EP2753352B2 (el)
JP (1) JP6121421B2 (el)
KR (1) KR101907434B1 (el)
CN (1) CN103957931B (el)
AU (1) AU2011298306B2 (el)
BR (1) BR112014004896B1 (el)
CA (1) CA2873272C (el)
CY (1) CY1118664T1 (el)
DK (1) DK2753352T4 (el)
ES (2) ES2631032T5 (el)
HR (1) HRP20170193T4 (el)
HU (1) HUE033342T2 (el)
LT (1) LT2753352T (el)
MX (1) MX350126B (el)
PL (1) PL2753352T5 (el)
PT (1) PT2753352T (el)
RS (1) RS55707B2 (el)
SI (1) SI2753352T2 (el)
SM (1) SMT201700124T1 (el)
WO (1) WO2012028741A1 (el)
ZA (1) ZA201400610B (el)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1169456B1 (en) * 1999-04-09 2012-07-11 Intercell USA, Inc. Recombinant production of Clostridium difficile Toxin A or Toxin B
JP6121421B2 (ja) 2010-09-03 2017-04-26 バルネバ オーストリア ジーエムビーエイチ Ｃ．ディフィシルの毒素ａおよび毒素ｂタンパク質の単離ポリペプチドならびにその使用
AU2012245904B2 (en) 2011-04-22 2016-04-21 Wyeth Llc Compositions relating to a mutant Clostridium difficile toxin and methods thereof
US9290565B2 (en) 2011-05-27 2016-03-22 Glaxosmithkline Biologicals, S.A. Immunogenic composition
AU2016203241B2 (en) * 2011-05-27 2018-05-10 Glaxosmithkline Biologicals S.A. Immunogenic composition
CN103974718A (zh) 2011-12-08 2014-08-06 诺华股份有限公司 基于艰难梭菌毒素的疫苗
AR089797A1 (es) 2012-01-27 2014-09-17 Merck Sharp & Dohme Vacunas contra clostridum difficile que comprenden toxinas recombinantes
US8986704B2 (en) 2012-07-06 2015-03-24 Valneva Austria Gmbh Mutant fragments of OspA and methods and uses relating thereto
BR122016023101B1 (pt) 2012-10-21 2022-03-22 Pfizer Inc Polipeptídeo, composição imunogênica que o compreende, bem como célula recombinante derivada de clostridium difficile
LT2928489T (lt) * 2012-12-05 2019-04-10 Glaxosmithkline Biologicals S.A. Imunogeninė kompozicija
GB201223342D0 (en) * 2012-12-23 2013-02-06 Glaxosmithkline Biolog Sa Immunogenic composition
GB2525177A (en) * 2014-04-14 2015-10-21 New Royal Holloway & Bedford Vaccine
WO2016131157A1 (en) * 2015-02-19 2016-08-25 Immune Biosolutions Inc Clostridium difficile toxins a and/or b antigen and epitope antibody, and pharmaceutical uses thereof
CN109311950A (zh) * 2016-03-21 2019-02-05 儿童医学中心公司 用于抑制wnt信号传导的组合物和方法
ES2957939T3 (es) 2017-04-13 2024-01-30 Valneva Austria Gmbh Polipéptidos de OspA multivalentes y métodos y usos relacionados con los mismos
CN112703006A (zh) 2018-06-19 2021-04-23 葛兰素史密丝克莱恩生物有限公司 免疫原性组合物
WO2020173928A1 (en) * 2019-02-25 2020-09-03 Previpharma Consulting Gmbh Epitopes of clostridium difficile toxins a and b and uses thereof
US20240026412A1 (en) 2020-04-09 2024-01-25 Valneva Austria Gmbh Improved methods of producing a lipidated protein
GB202205833D0 (en) 2022-04-21 2022-06-08 Glaxosmithkline Biologicals Sa Bacteriophage
US20250213667A1 (en) 2022-06-01 2025-07-03 Valneva Austria Gmbh Clostridium difficile vaccine
EP4658302A1 (en) 2023-02-02 2025-12-10 GlaxoSmithKline Biologicals S.A. Immunogenic composition

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US6018026A (en) 1988-01-22 2000-01-25 Zymogenetics, Inc. Biologically active dimerized and multimerized polypeptide fusions
US5997856A (en) 1988-10-05 1999-12-07 Chiron Corporation Method and compositions for solubilization and stabilization of polypeptides, especially proteins
CA2017507C (en) 1989-05-25 1996-11-12 Gary Van Nest Adjuvant formulation comprising a submicron oil droplet emulsion
US5736139A (en) 1989-10-31 1998-04-07 Ochidian Pharmaceuticals, Inc. Treatment of Clostridium difficile induced disease
US5547871A (en) 1993-01-25 1996-08-20 American Cyanamid Company Heterologous signal sequences for secretion of insect controlling proteins
CA2560114A1 (en) 1994-07-15 1996-02-01 The University Of Iowa Research Foundation Immunomodulatory oligonucleotides
BR9509903A (pt) * 1994-10-24 1997-11-25 Ophidian Pharm Inc Proteína de fusão proteína de fus o solúvel composição de matéria célula hospedeira processo para gerar uma antiotoxina neutralizante dirigida contra toxina tipo a de clostridium botulinum anticorpo processo para purificar uma proteina de fusão recombinante derivada de uma toxina tipo a de clostridium botulinum processo para gerar uma antitoxina neutralizante dirigida contra toxina tipo b de clostridium difficile anticorpo processo de tratemento processo para gerar uma antitoxina neutralizante dirigida contra toxina tipo a de clostridium difficile composição processo para vacinar um individuo para produzir antitoxina neutralizante dirigida contra toxina de clostridium difficile processo a detecção de antigenos de clostridium difficile em uma amosta processo de purificação de toxinas de clostridium difficile de uma cultura e processo de generação de uma forma dosagem sólida de uma antitoxina de ave dirigida contra uma proteina de toxina clostridial
DE69610106D1 (de) 1995-07-07 2000-10-05 Oravax Inc Toxine und toxoide von clostridium difficile als schleimhautadjuvans
US5919463A (en) 1995-07-07 1999-07-06 Oravax, Inc. Clostridium difficle toxins as mucosal adjuvants
JP2001501930A (ja) 1996-10-04 2001-02-13 オークランド ユニサーヴィスィズ リミテッド 神経酵素の調節
WO1998029134A2 (en) 1996-12-31 1998-07-09 Altea Technologies, Inc. Microporation of tissue for delivery of bioactive agents
EP1169456B1 (en) 1999-04-09 2012-07-11 Intercell USA, Inc. Recombinant production of Clostridium difficile Toxin A or Toxin B
US6733760B1 (en) 1999-04-09 2004-05-11 Techlab, Inc. Recombinant toxin A/toxin B vaccine against Clostridium difficile
AT408721B (de) 1999-10-01 2002-02-25 Cistem Biotechnologies Gmbh Pharmazeutische zusammensetzung enthaltend ein antigen
AT409085B (de) 2000-01-28 2002-05-27 Cistem Biotechnologies Gmbh Pharmazeutische zusammensetzung zur immunmodulation und herstellung von vakzinen
AT410173B (de) 2000-06-08 2003-02-25 Cistem Biotechnologies Gmbh Antigene zusammensetzung
HU228264B1 (en) 2000-06-08 2013-02-28 Intercell Ag Immunostimulatory oligodeoxynucleotides
CA2418854A1 (en) 2000-08-17 2002-02-21 Jorg Fritz A vaccine which comprises at least one antigen and a cathelididin derived antimicrobial peptide or a derivative thereof
AT410635B (de) 2000-10-18 2003-06-25 Cistem Biotechnologies Gmbh Vakzin-zusammensetzung
WO2002094845A2 (en) 2001-05-21 2002-11-28 Intercell Ag Method for stabilising of nucleic acids
AU2002358616A1 (en) 2001-12-07 2003-06-17 Intercell Ag Immunostimulatory oligodeoxynucleotides
JP4588763B2 (ja) * 2004-02-06 2010-12-01 ユニバーシティー オブ マサチューセッツ クロストリジウム・ディフィシル（Ｃｌｏｓｔｒｉｄｉｕｍｄｉｆｆｉｃｉｌｅ）毒素に対する抗体およびその使用
ATE520406T1 (de) 2004-08-23 2011-09-15 Teva Pharma Kristalline form des ibandronat-natriums
WO2007146139A2 (en) * 2006-06-08 2007-12-21 Cornell Research Foundation, Inc. Codon-optimized dna molecules encoding the receptor binding domains of clostridium difficile toxins a and b
EP1921149A1 (en) * 2006-11-13 2008-05-14 AEterna Zentaris GmbH Microorganisms as carriers of nucleotide sequences coding for antigens and protein toxins, process of manufacturing and uses thereof
WO2008152429A1 (en) * 2007-06-14 2008-12-18 Health Protection Agency Chemically modified peptides with improved immunogenicity
CN101855336B (zh) 2007-09-14 2019-07-30 赛诺菲巴斯德生物制剂有限责任公司 含艰难梭菌类毒素a和b的药物组合物
US20120020996A1 (en) * 2008-08-06 2012-01-26 Jonathan Lewis Telfer Vaccines against clostridium difficile and methods of use
WO2011060431A2 (en) † 2009-11-16 2011-05-19 University Of Maryland Baltimore Multivalent live vector vaccine against clostridium difficile-associated disease
GB0921288D0 (en) * 2009-12-04 2010-01-20 Health Prot Agency Therapies for preventing or suppressing clostridium difficile infection
EP2558493B1 (en) 2010-04-15 2019-09-18 Progenics Pharmaceuticals, Inc. Antibodies for the treatment of clostridium difficile-associated infection and disease
JP6121421B2 (ja) 2010-09-03 2017-04-26 バルネバ オーストリア ジーエムビーエイチ Ｃ．ディフィシルの毒素ａおよび毒素ｂタンパク質の単離ポリペプチドならびにその使用
AU2012245904B2 (en) * 2011-04-22 2016-04-21 Wyeth Llc Compositions relating to a mutant Clostridium difficile toxin and methods thereof
US9290565B2 (en) 2011-05-27 2016-03-22 Glaxosmithkline Biologicals, S.A. Immunogenic composition
GB201206070D0 (en) * 2012-04-04 2012-05-16 Health Prot Agency Clostridium difficile antigens
LT2928489T (lt) * 2012-12-05 2019-04-10 Glaxosmithkline Biologicals S.A. Imunogeninė kompozicija
GB201223342D0 (en) 2012-12-23 2013-02-06 Glaxosmithkline Biolog Sa Immunogenic composition
US9181632B1 (en) * 2013-09-09 2015-11-10 Merck Sharp & Dohme Corp. C.difficile toxin B CROP domain peptides, antibodies and complexes thereof

Also Published As

Publication number Publication date
MX350126B (es) 2017-08-28
JP2014525249A (ja) 2014-09-29
LT2753352T (lt) 2017-05-25
EP3167899A1 (en) 2017-05-17
EP2753352B2 (en) 2022-08-10
US20210121554A1 (en) 2021-04-29
US12324831B2 (en) 2025-06-10
AU2011298306B2 (en) 2017-10-19
ZA201400610B (en) 2015-09-30
US20250360191A1 (en) 2025-11-27
US11478540B2 (en) 2022-10-25
KR20140057315A (ko) 2014-05-12
HK1200357A1 (en) 2015-08-07
US10821166B2 (en) 2020-11-03
HRP20170193T1 (hr) 2017-06-02
EP2753352A1 (en) 2014-07-16
US11357844B2 (en) 2022-06-14
US20190290747A1 (en) 2019-09-26
CA2873272A1 (en) 2012-03-08
MX2014002595A (es) 2014-10-13
US20230173052A1 (en) 2023-06-08
SMT201700124T1 (it) 2017-05-08
US20210393761A1 (en) 2021-12-23
DK2753352T3 (da) 2017-03-06
EP2753352B1 (en) 2017-01-25
SI2753352T1 (sl) 2017-06-30
US9598472B2 (en) 2017-03-21
DK2753352T5 (da) 2017-05-01
US20150056238A1 (en) 2015-02-26
CN103957931A (zh) 2014-07-30
PT2753352T (pt) 2017-03-08
AU2011298306A1 (en) 2014-02-20
SI2753352T2 (sl) 2022-10-28
HRP20170193T4 (hr) 2022-09-02
ES2631032T3 (es) 2017-08-25
CN103957931B (zh) 2017-10-24
RS55707B2 (sr) 2022-10-31
ES2867375T3 (es) 2021-10-20
PL2753352T5 (pl) 2022-10-17
JP6121421B2 (ja) 2017-04-26
WO2012028741A1 (en) 2012-03-08
BR112014004896B1 (pt) 2023-02-14
PL2753352T3 (pl) 2017-07-31
ES2631032T5 (es) 2022-10-26
EP3167899B1 (en) 2021-03-24
CA2873272C (en) 2020-10-27
BR112014004896A2 (pt) 2021-01-26
US10357557B2 (en) 2019-07-23
EP3895728A1 (en) 2021-10-20
HUE033342T2 (en) 2017-11-28
KR101907434B1 (ko) 2018-10-12
US20170239340A1 (en) 2017-08-24
DK2753352T4 (da) 2022-09-12
RS55707B1 (sr) 2017-07-31

Similar Documents

Publication Publication Date Title
CY1118664T1 (el) Απομονωμενο πολυπεπτιδιο των πρωτεϊνων τοξινης α και τοξινης β toy c. difficile και χρησεις αυτου
CY1119265T1 (el) Κατασκευες νανοσωματων τρισθενους αντι ανθρωπινου αναπνευστικου συγκυτιακου ιου (hrsv) για την προληψη και/ή θεραπεια λοιμωξεων της αναπνευστικης οδου
PH12013502234A1 (en) Amino acid sequences directed against il-17a, il-17f and/or il17-a/f and polypeptides comprising the same
NZ602943A (en) Modified binding proteins inhibiting the vegf-a receptor interaction
MX2014011459A (es) Proteinas nutritivas cargadas y metodos.
NZ602634A (en) Vista regulatory t cell mediator protein, vista binding agents and use thereof
MX2014005108A (es) Constructos de polipeptidos y sus usos.
NZ712148A (en) Wt1 antigen peptide conjugate vaccine
EA201892619A1 (ru) Иммуноконъюгаты, содержащие мутантные полипептиды интерлейкина-2
NZ600732A (en) Oxyntomodulin peptide analogue
IN2014KN01713A (el)
IN2014KN01714A (el)
IN2014KN01716A (el)
MX2011011132A (es) Peptido auxiliar del antigeno del cancer.
NZ628446A (en) Fibronectin based scaffold domain proteins that bind to myostatin
AR086199A1 (es) Composiciones relacionadas con una toxina de clostridium difficile mutante y sus metodos
MX371202B (es) Receptores de células t humanas con alta afinidad modificados por medio de manipulación genética.
ES2585328T3 (es) Variantes no lipidadas de antígenos ORF2086 de Neisseria meningitidis
NZ703560A (en) Method for activating helper t cell
AR079114A1 (es) Proteinas de enlace de antigenos anti-orai1 y usos de las mismas
MX2016008355A (es) Anticuerpos que comprenden extensiones de polipeptidos de cadena ligera en el extremo c y conjugados y metodos de uso de estos.
EA201491643A1 (ru) Идентификация мутаций канал-опсина-2 (chop2) и способы применения
NZ706884A (en) Fc gamma receptor iib variants
GB2517354A (en) Hydrochloride salt of peptide and its use in combination with other peptides for immunotherapy
WO2013054110A3 (en) Compositions for binding to amyloid proteins